Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #13 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Biocon Limited (this stock) | 60,348 | 597.3 | 1.0% | 6.9% | 0.14% | 43 | 44 | 28 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 4,336 | 128 | 137 | ₹ |
| March 31, 2026 | 4,517 | 248 | 199 | ₹ |
| Dec. 31, 2025 | 4,173 | -68 | -52 | ₹ |
| Sept. 30, 2025 | 4,296 | 171 | 133 | ₹ |
| June 30, 2025 | 3,942 | 97 | 89 | ₹ |
| March 31, 2025 | 4,417 | 487 | 459 | ₹ |
| Dec. 31, 2024 | 3,821 | 156 | 81 | ₹ |
| Sept. 30, 2024 | 3,590 | 98 | 27 | ₹ |
| June 30, 2024 | 3,433 | 1,146 | 862 | ₹ |
| March 31, 2024 | 3,917 | 322 | 223 | ₹ |
| Dec. 31, 2023 | 3,954 | 832 | 753 | ₹ |
| Sept. 30, 2023 | 3,462 | 238 | 173 | ₹ |
| June 30, 2023 | 3,423 | 217 | 149 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 16,927 | 448 | 369 |
| March 31, 2025 | 15,262 | 1,887 | 1,429 |
| March 31, 2024 | 14,756 | 1,609 | 1,298 |
| March 31, 2023 | 11,174 | 1,064 | 643 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 1,994 | -2,082 | -924 | 1,798 | 196 |
| March 31, 2025 | 4,061 | -234 | -1,854 | 2,137 | 1,925 |
| March 31, 2024 | 2,954 | -1,004 | -2,333 | 1,680 | 1,273 |
| March 31, 2023 | 1,852 | -14,282 | 13,049 | 1,596 | 256 |
| March 31, 2022 | 1,177 | -1,699 | 242 | 1,698 | -521 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 63,651 | 36,622 | 33,221 | 4,078 | 10,746 | 17,180 | 14,069 | 2,416 | 9,473 | 6,086 |
| March 31, 2025 | 58,797 | 27,712 | 21,044 | 5,350 | 12,405 | 16,286 | 14,334 | 3,227 | 8,708 | 4,931 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
